Innovax-ND-IBD-ILT (--) - Concentrate and solvent for suspension for injection
Innovax-ND-IBD-ILT (--) - Concentrate and solvent for suspension for injection
Authorised
- Turkey herpesvirus, strain HVT/ND/IBD/ILT (cell-associated), expressing fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus and gD and gI glycoproteins genes of Infectious laryngotracheitis virus, Live
Product identification
Medicine name:
Innovax-ND-IBD-ILT (--) - Concentrate and solvent for suspension for injection
Active substance:
- Turkey herpesvirus, strain HVT/ND/IBD/ILT (cell-associated), expressing fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus and gD and gI glycoproteins genes of Infectious laryngotracheitis virus, Live
Target species:
-
Chicken
-
Chicken (embryonated eggs)
Route of administration:
-
In ovo
-
Subcutaneous use
Product details
Active substance and strength:
-
Turkey herpesvirus, strain HVT/ND/IBD/ILT (cell-associated), expressing fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus and gD and gI glycoproteins genes of Infectious laryngotracheitis virus, LivePresentation_strength:10^3.2 – 10^4.6 PFU Reference:In House Index:0
Pharmaceutical form:
-
Concentrate and solvent for suspension for injection
Withdrawal period by route of administration:
-
In ovo
-
Chicken
-
Not applicable0dayZero days
-
-
Chicken (embryonated eggs)
-
Not applicable0dayZero days
-
-
-
Subcutaneous use
-
Chicken
-
Not applicable0dayZero days
-
-
Chicken (embryonated eggs)
-
Not applicable0dayZero days
-
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI01AD20
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Austria
-
Belgium
-
Bulgaria
-
Croatia
-
Cyprus
-
Czechia
-
Denmark
-
Estonia
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Iceland
-
Ireland
-
Italy
-
Latvia
-
Liechtenstein
-
Lithuania
-
Luxembourg
-
Malta
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
Package description:
- Packaging:Concentrate: ampoule (Type I glass), Package_size:Concentrate: 1 ampoule, Content:Concentrate: 2000 doses
- Packaging:Concentrate: ampoule (Type I glass), Package_size:Concentrate: 1 ampoule, Content:Concentrate: 4000 doses
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application - new active substance (Article 8 of Regulation (EU) 2019/6)
Marketing authorisation holder:
- Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
- Intervet International B.V.
Responsible authority:
- European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
English (PDF)
Download Published on: 18/07/2025
Bulgarian (PDF)
Published on: 18/07/2025
Croatian (PDF)
Published on: 18/07/2025
Czech (PDF)
Published on: 18/07/2025
Danish (PDF)
Published on: 18/07/2025
Dutch (PDF)
Published on: 18/07/2025
Estonian (PDF)
Published on: 18/07/2025
Finnish (PDF)
Published on: 18/07/2025
French (PDF)
Published on: 18/07/2025
German (PDF)
Published on: 18/07/2025
Greek (PDF)
Published on: 18/07/2025
Hungarian (PDF)
Published on: 18/07/2025
Icelandic (PDF)
Published on: 18/07/2025
Italian (PDF)
Published on: 18/07/2025
Latvian (PDF)
Published on: 18/07/2025
Lithuanian (PDF)
Published on: 18/07/2025
Maltese (PDF)
Published on: 18/07/2025
Norwegian (PDF)
Published on: 18/07/2025
Polish (PDF)
Published on: 18/07/2025
Portuguese (PDF)
Published on: 18/07/2025
Romanian (PDF)
Published on: 18/07/2025
Slovak (PDF)
Published on: 18/07/2025
Slovenian (PDF)
Published on: 18/07/2025
Spanish (PDF)
Published on: 18/07/2025
Swedish (PDF)
Published on: 18/07/2025
